‘Regulatory Flexibility’ For Innovent/Lilly’s Sintilimab Not Warranted, US FDA Says

Bending over backwards
FDA is not exactly bending over backwards to approve sintilimab. • Source: Alamy

More from US FDA Performance Tracker

More from Regulatory Trackers